Tsumura & Co.
General ticker "TSMRF" information:
- Sector: Health Care
- Industry: Drug Manufacturers - Specialty & Generic
- Capitalization: $2.0B (TTM average)
Tsumura & Co. does not follow the US Stock Market performance with the rate: -44.1%.
Estimated limits based on current volatility of 0.0%: low 23.20$, high 23.20$
Factors to consider:
- Company pays dividends (annually): last record date 2025-09-30, amount 0.46$ (Y1.98%)
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-03-31 to 2027-03-31
- 2025-03-31 to 2026-03-31 estimated range: [20.91$, 32.41$]
- 2026-03-31 to 2027-03-31 estimated range: [18.89$, 29.90$]
Financial Metrics affecting the TSMRF estimates:
- Positive: with PPE of 10.1 at the end of fiscal year the price was neutral
- Positive: Operating profit margin, % of 22.16 > 18.64
- Negative: 0.01 < Interest expense per share per price, % of 0.16
- Positive: 6.82 < Operating cash flow per share per price, % of 10.55
- Positive: -14.38 < Investing cash flow per share per price, % of -7.79
- Negative: negative Industry operating cash flow (median)
- Positive: Shareholder equity ratio, % of 64.72 > 63.39
Short-term TSMRF quotes
Long-term TSMRF plot with estimates
Financial data
| YTD | 2023-03-31 | 2024-03-31 | 2025-03-31 |
|---|---|---|---|
| Operating Revenue | ¥140,043.00MM | ¥150,845.00MM | ¥181,093.00MM |
| Operating Expenses | ¥119,127.00MM | ¥130,828.00MM | ¥140,968.00MM |
| Operating Income | ¥20,916.00MM | ¥20,017.00MM | ¥40,125.00MM |
| Non-Operating Income | ¥2,102.00MM | ¥3,719.00MM | ¥5,434.00MM |
| Interest Expense | ¥256.00MM | ¥330.00MM | ¥518.00MM |
| R&D Expense | ¥7,594.00MM | ¥8,288.00MM | ¥0.00MM |
| Income(Loss) | ¥23,018.00MM | ¥23,736.00MM | ¥45,559.00MM |
| Taxes | ¥5,632.00MM | ¥5,689.00MM | ¥11,035.00MM |
| Profit(Loss)* | ¥16,482.00MM | ¥16,707.00MM | ¥32,428.00MM |
| Stockholders Equity | ¥252,045.00MM | ¥270,801.00MM | ¥300,528.00MM |
| Inventory | ¥101,725.00MM | ¥117,616.00MM | ¥133,783.00MM |
| Assets | ¥396,813.00MM | ¥428,254.00MM | ¥464,380.00MM |
| Operating Cash Flow | ¥16,452.00MM | ¥5,608.00MM | ¥33,823.00MM |
| Capital expenditure | ¥14,708.00MM | ¥20,057.00MM | ¥29,794.00MM |
| Investing Cash Flow | ¥-15,493.00MM | ¥-19,351.00MM | ¥-24,974.00MM |
| Financing Cash Flow | ¥24,423.00MM | ¥-4,417.00MM | ¥-19,871.00MM |
| Earnings Per Share** | ¥215.63 | ¥219.82 | ¥427.15 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.